Whalesbook
Strong Revenue Growth, Falling Profits
Indegene reported a mixed financial picture for the fourth quarter of fiscal year 2026. Revenue from operations jumped 32.8% year-on-year to ₹1,003.4 crore, contributing to a full-year revenue increase of 23.6% to ₹3,510.5 crore. However, net profit for the quarter fell sharply by 32.2% year-on-year to ₹79.7 crore. Profit margins also tightened, with EBITDA margins narrowing to 16.3% from 19.5% a year earlier. This decline in profitability was linked to a 57.6% rise in depreciation and amortization expenses for the full year, primarily due to assets from recent acquisitions. Despite the revenue gains, the stock closed down 0.41% on April 29, 2026, as investors focused on earnings concerns.
Health-Tech Sector Trends and Peer Valuations
The company operates in the growing health-tech and IT services sectors, which offer significant opportunities alongside challenges. While the Indian IT services sector expects modest 2-3% revenue growth in USD for FY2026, the health-tech domain is set for substantial expansion. Global AI in healthcare is predicted to grow at a 41.8% CAGR. Indegene's price-to-earnings (P/E) ratio of around 30-31.7x is in line with peers like L&T Technology Services (LTTS) and Happiest Minds. Tata Elxsi trades at a higher valuation. However, Indegene's valuation, when compared to healthcare service providers like Dr. Lal Pathlabs (29.3x), suggests investors are paying a premium for its growth prospects, a premium that recent margin performance might struggle to justify.
Acquisitions Drive Costs, Squeeze Margins
Indegene's strategy of growth through acquisitions, such as BioPharm and WARN & Co., has increased intangible assets and depreciation costs. Chief Financial Officer Suhas Prabhu noted that one-time merger and acquisition costs, including a ₹20.3 crore loss in Q4, contributed to the profit drop. The consistent margin decline, however, raises questions beyond temporary M&A impacts. The company also carries significant leverage, with a debt-to-equity ratio of 7.62. This high debt level amplifies financial risks if profitability does not improve alongside revenue growth. The market's current focus on stable earnings, rather than just revenue increases, highlights the risk tied to this acquisition-focused approach.
Analysts Remain Positive Despite Profit Concerns
Analysts largely maintain a positive view on Indegene, with most recommending 'Buy' or 'Outperform' and an average 12-month price target around INR 568.57. For example, ICICI Securities reiterated a 'BUY' rating, citing confidence in sector demand and the company's AI strategy. This optimistic outlook contrasts with the recent earnings report, which revealed declining net profit and squeezed margins. The company's valuation suggests an expectation of steady profit growth, which recent results indicate could be challenged by integration costs and operational efficiency. Some analysts have adjusted their fair value estimates, reflecting a recalibration of future projections.
Future Outlook and Valuation Challenges
Indegene's management remains optimistic, forecasting a 5-8% CAGR for the health-tech sector between FY26 and FY28 and seeing a stronger biotech deal pipeline. To align with these growth forecasts, analysts have set future price targets, such as ICICI Securities' March 2027 target of INR 620, based on a forward P/E multiple of 24x. This forward P/E is lower than the current trailing P/E, implying an expectation of significant future earnings growth needed to support the valuation. Given the recent margin squeeze, Indegene's success in converting its strong revenue growth into sustainable profits will be key. Effectively integrating acquired companies and leveraging AI for productivity gains will be crucial for meeting investor expectations and navigating the competitive market.